Tumour conference simulation for surgeons - HCC and liver metastases

Target group: Liver surgeons and surgical oncologists

Number of participants: 10-15

Duration: 1,5 days

19 CME credit points (Continuing Medical Education)


  • Prof. Dr. med. Christiane Bruns
    Director of the Clinic for General, Visceral and Vascular Surgery, University of Cologne

  • Prof. Dr. med. Jens Ricke
    Institute of Clinical Radiology, University Hospital of Munich

Course objective: This course focusses on the role of liver surgery in the context of advanced tumour diseases. Due to modern surgical and radiologically interventional procedures (volume-hypertrophy by PVE or SIRT), even patients with advanced hepatic tumour disease can be treated interventionally. Today, the optimal individual and usually multi-modal therapy plan is often deter-
mined in interdisciplinary tumour conferences. Therapy decisions should be made based on the current best evidence in surgical procedures (minimally invasive liver surgery, two-stage resection, ALPPS, liver-first approach), adjuvant and neoadjuvant chemotherapy concepts and locally ablative procedures (radio frequency ablation, SIRT, TACE, etc.).
This course presents multi-modal therapy concepts for primary and secondary liver tumours as well as current best evidence. These concepts will be applied by participants in an interactive simulation of an interdisciplinary tumour experts’ conference using a broad range of case examples. Performance tests at the end of each session will help participants to monitor their own learning process.

Day 1:

Hepatocellular carcinoma

3:00 p.m.     Greeting and introduction into the interdisciplinarity in HCC management
3:15 p.m.     HCC treatment per guidelines (hepatologist)
3.40 p.m.    Surgery on patients with BCLC 0 and A (surgeon)
3:50 p.m.    RFA on patients with BCLC 0 and A (radiologist)
4:00 p.m.     Case discussion: ablation versus resection versus combination therapy, therapy concepts beyond the classical guidelines
4.20 p.m.     Evidence of SIRT and difference to TACE (radiologist)
4:35  p.m.    Surgery on patients with BCLC B (surgeon)
4.45 p.m.    Case discussion: SIRT for induction of the volume hypertrophy 
5.05 p.m.    Break
5.20 p.m.    Liver function: what the practitioner needs to know (hepatologist)
6.00 p.m.    Interactive case discussion and tumour conference simulation 
7.00 p.m.    Interim course evaluation 

(end approx. 7.30 p.m.) 

Day 2:

Metastasising colorectal carcinoma

8.30 a.m.    Introduction into the systemic and personalised treatment of CRC (oncologist) 
9.15 a.m.    Expanding the limits of surgery and local therapy: Procedure for liver hypertrophy induction (surgeon)
9.25 a.m.    Ablation of liver metastases (radiologist)
9.35 a.m.    Case discussion: RFA versus resection versus combination therapy
10.00 a.m.    SIRT for „liver-only“ mCRC: arguments from the oncologist’s point of view (oncologist and surgeon)
10.45 a.m.    IInteractive case discussion and tumour conference simulation
11.30 a.m.    Break

Neuroendocrin carcinomas

11.45 a.m.    ENETS guidelines 2016: what is new? (endocrinologist)
12.30 p.m.    Evidence of SIRT for NET and difference to TACE (oncologist)
12.45 p.m.    Minimally invasive surgery for metastasising NET? (surgeon)
1.00 p.m.    Interactive case discussion and tumour conference simulation
1.45 p.m.    Lunch break

Interdisciplinary clinical management of SIRT patients

2.15 p.m.    Management of SIRT patients: (surgeon)
    – before the intervention: preparation, clinical  parameters for determining the indication
    – after the intervention: monitoring, follow-up care
3.00 p.m.    Prevention, recognition and management of interventional complications (radiologist)
3.45 p.m. Course evaluation and final test 
(end: approx. 4.15 p.m.)